1:26 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177.

BMS will receive an undisclosed upfront payment and is eligible for milestones. The companies will share costs and profits.

Next half, the partners plan to begin Phase II testing of BMS-986177 to prevent secondary stroke.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD